Patients With Acute Phlebitis can be Treated Safely With Great Saphenous Vein (GSV) Ablation

Eight trials were reviewed (ATTRACT, CAVENT, CLOUT, VIRTUS, VERNACULAR, VIVO, ACCESS, and ABRE).Three trialsd ATTRACT, CAVENT, and ACCESSdwere designed to assess efficacy of DVT management with aim to reduce post-thrombotic syndrome and recruited relatively lesser females with M:F ratios of 1.6, 1.7, and 2.1, respectively.Four trials assessing stent placement-based outcomes had fewer male participants, all with M:F ratios <1, with the lowest ratio in the VIVO trial.One trial studying mechanical thrombectomy had an optimal M:F ratio of 1.Three of these trials did not report the racial composition of enrollees.No study used EIR or other tools to calculate sample sizes in the treatment or control arm for optimal sex or race representation in the conducted trials.Conclusions: The findings highlight significant sex disparities in DVT trials, with more males in trials focused on post-thrombotic syndrome and more females in stent placement studies.The absence of racial reporting and thorough calculation by EIR highlights an urgent need for more inclusive recruitment strategies to ensure DVT trial outcomes truly reflect and benefit diverse patient populations.